Skip to main navigation
  • Recent News
  • Investors
  • Contact Us
Avadel pharmaceutical logo
  • Home
  • About Us
  • Our Focus
  • Culture & Careers
  • Recent News
  • Investors
  • Contact Us

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases

Press Releases

Keyword Search

08/31/23

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
08/09/23

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-- Successfully commenced U.S. commercial launch of LUMRYZ™ -- -- Received final FDA approval for LU...
Printer Friendly Version
08/03/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
08/02/23

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
DUBLIN, Ireland , Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
07/20/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
07/06/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/22/23

Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
DUBLIN, Ireland , June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
06/14/23

Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
DUBLIN, Ireland , June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/13/23

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
Among 100 clinicians, the primary driver of overall oxybate choice, potential to improve patient qua...
Printer Friendly Version
06/06/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , June 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/05/23

Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightl...
Printer Friendly Version
06/01/23

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
DUBLIN, Ireland , June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
05/31/23

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growi...
Printer Friendly Version
05/04/23

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate fo...
Printer Friendly Version
05/03/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN , May 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focus...
Printer Friendly Version
05/01/23

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; ...
Printer Friendly Version
04/20/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , April 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
04/10/23

Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
DUBLIN, Ireland , April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
Printer Friendly Version
04/03/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN , April 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company foc...
Printer Friendly Version
03/30/23

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to ...
Printer Friendly Version
03/29/23

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...
Printer Friendly Version
03/29/23

Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ...
Printer Friendly Version
03/29/23

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares
DUBLIN, Ireland , March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: ...
Printer Friendly Version
03/29/23

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic ...
Printer Friendly Version
03/22/23

Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approv...
Printer Friendly Version
03/21/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
03/02/23

Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension
- Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland ...
Printer Friendly Version
02/16/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
02/08/23

Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
DUBLIN, Ireland , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...
Printer Friendly Version
02/03/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
01/24/23

Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediat...
Printer Friendly Version
01/23/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
01/10/23

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Jan. 10, 2023 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts
  • About Us
  • Our Focus
  • Culture & Careers
  • Recent News
  • Investors
  • Contact Us
  • Home
  • About Us
  • Our Focus
  • Culture & Careers
  • Contact Us
  • Recent News
  • Investors
  • Privacy Policy
  • Corporate Compliance
  • Terms and Conditions

Avadel, the Avadel logo, the droplet brand mark, and other brands are trademarks of an Avadel company. © 2022 Avadel. All rights reserved.

PM-US-AVGEN-0132

We Care About Your Privacy

This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our updated Privacy Policy.

You are about to leave the Avadel website.

Do you want to continue?

Avadel is not responsible for the content or availability of third party sites.